Cargando…

Tumour blood flow for prediction of human prostate cancer aggressiveness: a study with Rubidium-82 PET, MRI and Na(+)/K(+)-ATPase-density

PURPOSE: Tumour blood flow (TBF) is a crucial determinant of cancer growth. Recently, we validated Rubidium-82 ((82)Rb) positron emission tomography (PET) for TBF measurement in prostate cancer (PCa) and found TBF and cancer aggressiveness positively correlated. The aims of the present study were to...

Descripción completa

Detalles Bibliográficos
Autores principales: Jochumsen, Mads Ryø, Sörensen, Jens, Pedersen, Bodil Ginnerup, Nyengaard, Jens Randel, Krag, Søren Rasmus Palmelund, Frøkiær, Jørgen, Borre, Michael, Bouchelouche, Kirsten, Tolbod, Lars Poulsen
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7835182/
https://www.ncbi.nlm.nih.gov/pubmed/32808078
http://dx.doi.org/10.1007/s00259-020-04998-2
_version_ 1783642459984625664
author Jochumsen, Mads Ryø
Sörensen, Jens
Pedersen, Bodil Ginnerup
Nyengaard, Jens Randel
Krag, Søren Rasmus Palmelund
Frøkiær, Jørgen
Borre, Michael
Bouchelouche, Kirsten
Tolbod, Lars Poulsen
author_facet Jochumsen, Mads Ryø
Sörensen, Jens
Pedersen, Bodil Ginnerup
Nyengaard, Jens Randel
Krag, Søren Rasmus Palmelund
Frøkiær, Jørgen
Borre, Michael
Bouchelouche, Kirsten
Tolbod, Lars Poulsen
author_sort Jochumsen, Mads Ryø
collection PubMed
description PURPOSE: Tumour blood flow (TBF) is a crucial determinant of cancer growth. Recently, we validated Rubidium-82 ((82)Rb) positron emission tomography (PET) for TBF measurement in prostate cancer (PCa) and found TBF and cancer aggressiveness positively correlated. The aims of the present study were to determine the ability of TBF for separating significant from insignificant PCa and to examine the relation to underlying Na(+)/K(+)-ATPase density, which is relevant as (82)Rb is transported intracellularly via the Na(+)/K(+)-ATPase. METHODS: One hundred and two patients were included for pelvic (82)Rb PET scan prior to magnetic resonance imaging (MRI)-guided prostate biopsy. Findings constituted 100 PCa lesions (86 patients) and 25 benign lesions (16 patients). Tumours were defined on MRI and transferred to (82)Rb PET for TBF measurement. Immunohistochemical Na(+)/K(+)-ATPase staining was subsequently performed on biopsies. RESULTS: TBF was the superior predictor (rho = 0.68, p < 0.0001, inflammatory lesions excluded) of MRI-guided biopsy grade group (GG) over lowest apparent diffusion coefficient (ADC) value (rho = −0.23, p = 0.01), independent of ADC value and tumour volume (p < 0.0001). PET could separate GG-2-5 from GG-1 and benign lesions with an area under the curve (AUC), sensitivity, and specificity of 0.79, 96%, and 59%, respectively. For separating GG-3-5 from GG-1-2 and benign lesions the AUC, sensitivity, and specificity were 0.82, 95%, and 63%, respectively. Na(+)/K(+)-ATPase density per PCa cell profile was 38% lower compared with that of the benign prostate cell profiles. Neither cell density nor Na(+)/K(+)-ATPase density determined tumour (82)Rb uptake. CONCLUSION: TBF is an independent predictor of PCa aggressiveness and deserves more attention, as it may be valuable in separating clinically significant from insignificant PCa. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (10.1007/s00259-020-04998-2) contains supplementary material, which is available to authorized users.
format Online
Article
Text
id pubmed-7835182
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Springer Berlin Heidelberg
record_format MEDLINE/PubMed
spelling pubmed-78351822021-01-29 Tumour blood flow for prediction of human prostate cancer aggressiveness: a study with Rubidium-82 PET, MRI and Na(+)/K(+)-ATPase-density Jochumsen, Mads Ryø Sörensen, Jens Pedersen, Bodil Ginnerup Nyengaard, Jens Randel Krag, Søren Rasmus Palmelund Frøkiær, Jørgen Borre, Michael Bouchelouche, Kirsten Tolbod, Lars Poulsen Eur J Nucl Med Mol Imaging Original Article PURPOSE: Tumour blood flow (TBF) is a crucial determinant of cancer growth. Recently, we validated Rubidium-82 ((82)Rb) positron emission tomography (PET) for TBF measurement in prostate cancer (PCa) and found TBF and cancer aggressiveness positively correlated. The aims of the present study were to determine the ability of TBF for separating significant from insignificant PCa and to examine the relation to underlying Na(+)/K(+)-ATPase density, which is relevant as (82)Rb is transported intracellularly via the Na(+)/K(+)-ATPase. METHODS: One hundred and two patients were included for pelvic (82)Rb PET scan prior to magnetic resonance imaging (MRI)-guided prostate biopsy. Findings constituted 100 PCa lesions (86 patients) and 25 benign lesions (16 patients). Tumours were defined on MRI and transferred to (82)Rb PET for TBF measurement. Immunohistochemical Na(+)/K(+)-ATPase staining was subsequently performed on biopsies. RESULTS: TBF was the superior predictor (rho = 0.68, p < 0.0001, inflammatory lesions excluded) of MRI-guided biopsy grade group (GG) over lowest apparent diffusion coefficient (ADC) value (rho = −0.23, p = 0.01), independent of ADC value and tumour volume (p < 0.0001). PET could separate GG-2-5 from GG-1 and benign lesions with an area under the curve (AUC), sensitivity, and specificity of 0.79, 96%, and 59%, respectively. For separating GG-3-5 from GG-1-2 and benign lesions the AUC, sensitivity, and specificity were 0.82, 95%, and 63%, respectively. Na(+)/K(+)-ATPase density per PCa cell profile was 38% lower compared with that of the benign prostate cell profiles. Neither cell density nor Na(+)/K(+)-ATPase density determined tumour (82)Rb uptake. CONCLUSION: TBF is an independent predictor of PCa aggressiveness and deserves more attention, as it may be valuable in separating clinically significant from insignificant PCa. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (10.1007/s00259-020-04998-2) contains supplementary material, which is available to authorized users. Springer Berlin Heidelberg 2020-08-18 2021 /pmc/articles/PMC7835182/ /pubmed/32808078 http://dx.doi.org/10.1007/s00259-020-04998-2 Text en © The Author(s) 2020 Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.
spellingShingle Original Article
Jochumsen, Mads Ryø
Sörensen, Jens
Pedersen, Bodil Ginnerup
Nyengaard, Jens Randel
Krag, Søren Rasmus Palmelund
Frøkiær, Jørgen
Borre, Michael
Bouchelouche, Kirsten
Tolbod, Lars Poulsen
Tumour blood flow for prediction of human prostate cancer aggressiveness: a study with Rubidium-82 PET, MRI and Na(+)/K(+)-ATPase-density
title Tumour blood flow for prediction of human prostate cancer aggressiveness: a study with Rubidium-82 PET, MRI and Na(+)/K(+)-ATPase-density
title_full Tumour blood flow for prediction of human prostate cancer aggressiveness: a study with Rubidium-82 PET, MRI and Na(+)/K(+)-ATPase-density
title_fullStr Tumour blood flow for prediction of human prostate cancer aggressiveness: a study with Rubidium-82 PET, MRI and Na(+)/K(+)-ATPase-density
title_full_unstemmed Tumour blood flow for prediction of human prostate cancer aggressiveness: a study with Rubidium-82 PET, MRI and Na(+)/K(+)-ATPase-density
title_short Tumour blood flow for prediction of human prostate cancer aggressiveness: a study with Rubidium-82 PET, MRI and Na(+)/K(+)-ATPase-density
title_sort tumour blood flow for prediction of human prostate cancer aggressiveness: a study with rubidium-82 pet, mri and na(+)/k(+)-atpase-density
topic Original Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7835182/
https://www.ncbi.nlm.nih.gov/pubmed/32808078
http://dx.doi.org/10.1007/s00259-020-04998-2
work_keys_str_mv AT jochumsenmadsryø tumourbloodflowforpredictionofhumanprostatecanceraggressivenessastudywithrubidium82petmriandnakatpasedensity
AT sorensenjens tumourbloodflowforpredictionofhumanprostatecanceraggressivenessastudywithrubidium82petmriandnakatpasedensity
AT pedersenbodilginnerup tumourbloodflowforpredictionofhumanprostatecanceraggressivenessastudywithrubidium82petmriandnakatpasedensity
AT nyengaardjensrandel tumourbloodflowforpredictionofhumanprostatecanceraggressivenessastudywithrubidium82petmriandnakatpasedensity
AT kragsørenrasmuspalmelund tumourbloodflowforpredictionofhumanprostatecanceraggressivenessastudywithrubidium82petmriandnakatpasedensity
AT frøkiærjørgen tumourbloodflowforpredictionofhumanprostatecanceraggressivenessastudywithrubidium82petmriandnakatpasedensity
AT borremichael tumourbloodflowforpredictionofhumanprostatecanceraggressivenessastudywithrubidium82petmriandnakatpasedensity
AT bouchelouchekirsten tumourbloodflowforpredictionofhumanprostatecanceraggressivenessastudywithrubidium82petmriandnakatpasedensity
AT tolbodlarspoulsen tumourbloodflowforpredictionofhumanprostatecanceraggressivenessastudywithrubidium82petmriandnakatpasedensity